That was for the CCA expansion from 3 months ago which might not be significant enough unless those SD become PR or CR (most off these patients would have been enrolled at most 12 months ago when the expansion was announced so these data are at most only 9 months into the clinical trial), the market still want to see how CF33 is working on other cancer tumour since 16 months ago.
IMU Price at posting:
2.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)